Skip to main content
. Author manuscript; available in PMC: 2014 Feb 18.
Published in final edited form as: Nature. 2012 Jun 28;486(7404):532–536. doi: 10.1038/nature11156

Figure 3. Mutational analysis of the KRAS gene in patients.

Figure 3

(a) Mutational analysis of KRAS in chemorefractory patients. (b) Mutational analysis of the KRAS gene in patients who progressed on anti-EGFR antibodies. The results are based on assays performed by Deep sequencing technologies a: 454 pyrosequencing; b: BEAMing. (c) Dot plot of percentage of mutated KRAS alleles in chemorefractory and anti-EGFR resistant patients: p-value was calculated by two-tailed unpaired Mann-Whitney test.